<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 18:16:36[mciao0828] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<header>
<title>Surrogate endpoint</title>
<id>1180539</id>
<revision>
<id>220988158</id>
<timestamp>2008-06-22T15:11:38Z</timestamp>
<contributor>
<username>DOI bot</username>
<id>6652755</id>
</contributor>
</revision>
<categories>
<category>Epidemiology</category>
<category>Medical research</category>
<category>Medical terms</category>
</categories>
</header>
<bdy>

In <link xlink:type="simple" xlink:href="../717/241717.xml">
clinical trial</link>s, a <b>surrogate endpoint</b> (or <b>marker</b>) is a measure of effect of a certain treatment that may correlate with a <it>real</it> endpoint but doesn't necessarily have a guaranteed relationship.  The <institute wordnetid="108407330" confidence="0.8">
<association wordnetid="108049401" confidence="0.8">
<link xlink:type="simple" xlink:href="../174/46174.xml">
National Institutes of Health</link></association>
</institute>
 (USA) define surrogate endpoint as "a biomarker intended to substitute for a clinical endpoint".<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref><p>

Surrogate markers are used when the primary endpoint is undesired (e.g., death), or when the number of events is very small, thus making it impractical to conduct a clinical trial to gather a <link xlink:type="simple" xlink:href="../995/160995.xml">
statistically significant</link> number of endpoints.  The <link xlink:type="simple" xlink:href="../632/11632.xml">
FDA</link> will often accept evidence from <link xlink:type="simple" xlink:href="../717/241717.xml">
clinical trial</link>s that show a benefit to surrogate markers instead of to endpoints.</p>
<p>

A commonly used example is <link xlink:type="simple" xlink:href="../437/6437.xml">
cholesterol</link>.  While elevated cholesterol levels increase the likelihood for <link xlink:type="simple" xlink:href="../662/512662.xml">
heart disease</link>, the relationship is not linear - many people with normal cholesterol develop heart disease, and many with high cholesterol do not.  "Death from heart disease" is the endpoint of interest, but "cholesterol" is the surrogate marker.  A clinical trial may show that a particular drug (for example, <link xlink:type="simple" xlink:href="../659/635659.xml">
simvastatin</link> (Zocor)) is effective in reducing cholesterol, without showing directly that simvastatin prevents death.  Proof of Zocor's efficacy in reducing cardiovascular disease was only presented five years after its original introduction, and then only for <link xlink:type="simple" xlink:href="../005/3964005.xml">
secondary prevention</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref>  In another case, <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../872/441872.xml">
AstraZeneca</link></company>
 has been accused of marketing <link xlink:type="simple" xlink:href="../587/636587.xml">
rosuvastatin</link> (Crestor) without providing hard endpoint data, relying instead on surrogate endpoints.  The company counters that it had been tested on larger groups of patients than any other drug in the class, and that its effects should be comparable to the other statins.</p>
<p>

Examples of other surrogate markers include:
<list>
<entry level="1" type="bullet">

 fragmented blood cells are a surrogate marker for organ failure or stroke in <link xlink:type="simple" xlink:href="../537/472537.xml">
TTP</link>;</entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../494/1215494.xml">
S phase</link> duration may be used as a surrogate marker for breast cancer occurrence;</entry>
<entry level="1" type="bullet">

 <agglomeration wordnetid="107959269" confidence="0.8">
<collection wordnetid="107951464" confidence="0.8">
<bunch wordnetid="107959943" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<link xlink:type="simple" xlink:href="../678/1884678.xml">
CD4</link></group>
</bunch>
</collection>
</agglomeration>
 count is a surrogate marker for death from HIV infection.</entry>
</list>
</p>

<sec>
<st>
Criticism</st>
<p>

There have been a number of instances when studies using surrogate markers have been used to show benefit from a particular treatment, but later, a repeat study looking at endpoints has not shown a benefit, or even a harm.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref></p>

</sec>
<sec>
<st>
References</st>

<p>

<reflist>
<entry id="1">
Controlled Clinical Trials 22:485–502 (2001))</entry>
<entry id="2">
 <cite style="font-style:normal">Cohn JN&#32;(2004).&#32;"Introduction to Surrogate Markers". <it>Circulation</it>&#32;<b>109</b>: IV20&ndash;1.&#32;American Heart Association. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1161%2F01.CIR.0000133441.05780.1d">
10.1161/01.CIR.0000133441.05780.1d</weblink>. PMID 15226247.</cite>&nbsp;</entry>
<entry id="3">
 <cite style="font-style:normal">Pedersen TR, Olsson AG, Faergeman O, et al.&#32;(1998).&#32;"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)". <it>Circulation</it>&#32;<b>97</b>: 1453–1460.</cite>&nbsp;</entry>
<entry id="4">
 <cite style="font-style:normal">Psaty BM, Weiss NS, Furberg CD, et al.&#32;(1999).&#32;"Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease". <it>JAMA</it>&#32;<b>282</b>: 786&ndash;790. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1001%2Fjama.282.8.786">
10.1001/jama.282.8.786</weblink>. PMID 10463718.</cite>&nbsp;</entry>
</reflist>
</p>

</sec>
</bdy>
</article>
